ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2023

Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms

Martha Tsaliki1, Joshua Cavett1, Biji T. Kurien2, Christina Bruxvoort1, Robert Hal Scofield2 and Kristi A Koelsch3, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), classification criteria, Sjögren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Sjögren’s Syndrome (SS) diagnosis depends on clinic examinations that involve measurements of serum levels of anti-Ro\SSA, anti-La\SSB, and rheumatoid factor antibodies; the first is part of EULAR/ACR research classification criteria. Salivary glands in SS are sites where antibody secreting cells (ASC) accumulate and produce autoantibodies, which may be present in the saliva. Previously we found ASC producing anti-Ro/La in the salivary glands of SS and non-SS sicca (NSS) subjects without these antibodies in their serum. Patients that present to the clinic with Sjögren’s-like symptoms but do not meet the classification criteria are characterized NSS sicca, such patients are commonly understudied and excluded from clinical trials. We hypothesize that there is significant presence of autoantibodies in saliva of SS and NSS sicca subjects, and that there is a correlation between IgG/IgA levels and clinical characteristics.

Methods: We screened frozen whole unstimulated saliva samples from SS (n=200), NSS (n=200), and healthy controls (HCs; n=46) to detect salivary autoantibodies using ELISA. All subjects in this study have been evaluated and classified for SS. We validated our ELISA results using a capillary western blot method, and correlated disease manifestations among those with, and without, salivary antibodies.

Results: Our analysis showed that salivary anti-Ro antibodies were significantly more prevalent among pSS (80; 40%) compared to NSS sicca subjects (15; 7.5%) and HC (2; 4.35%). Similarly, salivary anti-La antibodies were significantly more common in pSS patients (80; 40%) compared to NSS sicca subjects (30; 7.5%), which in turn had higher anti-La antibody levels compared to HCs (1; 2.17%). A similar pattern holds for RF which were more common in saliva of pSS (55; 27%) and NSS sicca subjects (23; 11.5%) compared to HCs (2; 4.35%). NSS subjects with salivary anti-Ro/La were not statistically distinct in terms of disease manifestations compared to pSS subjects. In this cohort, 24 SS and 29 NSS sicca subjects were seronegative, but saliva positive, for anti-Ro antibodies. Lastly, NSS sicca subjects with salivary autoantibodies had more severe ocular (39%) and oral (65%) dryness compared to NSS without salivary autoantibodies and similar to that of SS subjects. Extraglandular manifestations were similar between SS and NSS with antibodies.

Conclusion: Our results indicate a subset of NSS sicca subjects who have salivary autoantibodies. These NSS subjects with salivary autoantibodies have clinical manifestations that are similar to SS; thus, is a new phenotype of disease, which may be early disease onset that will eventually seroconvert or remain seronegative as a distinct phenotype of the disease.


Disclosures: M. Tsaliki, None; J. Cavett, None; B. Kurien, None; C. Bruxvoort, None; R. Scofield, None; K. Koelsch, None.

To cite this abstract in AMA style:

Tsaliki M, Cavett J, Kurien B, Bruxvoort C, Scofield R, Koelsch K. Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/salivary-autoantibodies-in-sicca-patients-are-associated-with-dry-symptoms/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/salivary-autoantibodies-in-sicca-patients-are-associated-with-dry-symptoms/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology